Stock comparison
Grifols
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.48B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.43B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 62C | HAE |
| Benjamin Graham | 50C | 77B | HAE |
| Philip Fisher | 46D | 52C | HAE |
| Peter Lynch | 40D | 46D | HAE |
| Joel Greenblatt | 22F | 23F | HAE |
| Charlie Munger | 40D | 46D | HAE |
| Terry Smith | 43D | 47D | HAE |
Side-by-side metrics
| Metric | GRFS | HAE |
|---|---|---|
| Market cap | $6.48B | $2.43B |
| P/E (TTM) | 14.9x | 24.8x |
| EV/EBIT | 12.8x | 14.1x |
| ROIC (TTM) | 5.49% | 8.37% |
| Gross margin | 37.68% | 55.74% |
| Net margin | 5.58% | 7.29% |
| Revenue CAGR 5y | 10.02% | 7.65% |
| EPS CAGR 5y | 20.54% | 24.62% |
| Debt / Equity | 1.8x | 1.5x |
| Dividend yield | 1.65% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- Dividend yield1.65%vs 0.0%+100%
- Market cap$6.48Bvs $2.43B+63%
- P/E (TTM)14.9xvs 24.8x+40%
- Revenue CAGR 5y10.02%vs 7.65%+24%
HAE leads on
- ROIC (TTM)8.37%vs 5.49%+34%
- Gross margin55.74%vs 37.68%+32%
- Net margin7.29%vs 5.58%+23%
- EPS CAGR 5y24.62%vs 20.54%+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.